Treatment of the Acute Humoral Rejection in Kidney Allografts

• Autor(a) principal: Ribeiro, Adriana Reginato
• Data de Publicação: 2009
• Outros Autores: Berdichevski, Roberto Herz, Silva, Daniel Melquíades da, Mazzali, Marilda, Gonçalves, Luiz Felipe dos Santos, Manfro, Roberto Ceratti
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Brazilian Journal of Transplantation
• Texto Completo: https://bjt.emnuvens.com.br/revista/article/view/259
• topic: Transplante de Rim; Rejeição de Enxerto; Plasmaferese; Imunoglobinas; Soro Antilinfocitário; Muromonab-CD3; Renal Transplantation; Graft Rejection; Plasmapheresis; Intravenous Immunoglobulins; Antilynphocyte Serum; Renal transplantation, Graft Rejection, Plasmapheresis, Intravenous Immunoglobulins, Antilynphocyte Serum, Muromonab-CD3

Introduction: Acute humoral rejection (AHR) is a severe complication for renal transplantation usually causing a poor graft prognosis. A recent therapeutic approach with plasmapheresis and intravenous immunoglobulins (IVIg) has being proposed. Purpose: To describe the effectiveness of the treatment of AHR. Patients and methods: From January 2002 to April 2008 fifteen patients were diagnosed as having AHR, and they were treated with plasmapheresis and IVIg or ATG/OKT3 in our institution. Results: Reversal of AHR was attained in twelve (80%) patients. One-year patient and graft survivals were 100% and 73%, respectively. One successfully treated patient had the immunosuppressive regimen discontinued due the presence of sepsis, and the graft was subsequently lost. Conclusion: We concluded that this is an efficient therapeutic, allowing the survival of the majority of grafts.